← Back to patent-cliff list
Gallium (68Ga) oxodotreotide
Tier C — Watch / tradeGallium (68Ga) oxodotreotide
Advanced Accelerator Applications Sa
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：SSTR2
Brand：Netspot
Indications (approved)：Neuroendocrine tumour
Regional status
US
Approved
2016-06-01
EU
-
China
Phase III
2024-01-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gallium (68Ga) oxodotreotide?
Approved indications include: Neuroendocrine tumour.
When does the Gallium (68Ga) oxodotreotide patent expire?
No public expiry year is available for Gallium (68Ga) oxodotreotide yet; this page updates once verified.
How do I get a quote for Gallium (68Ga) oxodotreotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29